Sharps Technology (NASDAQ:STSS) & enVVeno Medical (NASDAQ:NVNO) Financial Analysis

Volatility & Risk

enVVeno Medical has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

Valuation & Earnings

This table compares enVVeno Medical and Sharps Technology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$23.52 million	($1.29)	-2.67
Sharps Technology	N/A	N/A	-$9.84 million	($8.08)	-0.27

enVVeno Medical is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares enVVeno Medical and Sharps Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-48.72%	-45.96%
Sharps Technology	N/A	-110.40%	-73.60%

Institutional & Insider Ownership

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 16.0% of enVVeno Medical shares are owned by insiders. Comparatively, 8.7% of Sharps Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

enVVeno Medical beats Sharps Technology on 5 of the 8 factors compared between the two stocks.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.